Cipla (EU) Limited on Monday announced a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & Medical Group to incorporate a joint venture in the United States.
According to a press statement, the primary goal of this joint venture is to develop and commercialise novel Cell therapy products for major unmet medical needs in the United States, Japan, and EU regions.
“Cipla (EU) Limited will secure a 35.2% stake in the joint venture company. By capitalising on Cipla’s leadership in product development and commercialisation and aligning with Kemwell’s expertise in biologics and Manipal’s expertise in healthcare delivery, this strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge Cell therapy products to cater to patients globally,” the company said in a statement.
“This joint venture reinforces our concerted efforts to move up the innovation curve and pioneer transformative treatments in the areas of stem cell and CAR T-cell therapies, enabled by advances in biotech, mRNA and cell-engineering research, that can make a difference to patient lives globally. As we steer Cipla into the future and lead with purpose, our partnership with Kemwell and Manipal Group will be integral in realising these advancements,” Umang Vohra, Managing Director & Global Chief Executive Officer, Cipla, said in a statement.
This marks the second joint venture between Cipla and Kemwell Biopharma, following the incorporation of Aspergen Inc., USA in 2022 for the development, manufacturing, and commercialization of biosimilars for global markets.
Aspergen Inc. is actively developing two projects, with several others under evaluation, accelerating Cipla’s global lung leadership agenda and strengthening the company’s position in the biosimilar market for long-term, diversified growth, it added.
